Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III Trial
Xuan-Yi Wang,Syed Faisal Mahmood,Fang Jin,Wee Kooi Cheah,Muhammad Ahmad,Mian Amjad Sohail,Waheed Ahmad,Vijaya K. Suppan,Muneeba Ahsan Sayeed,Shobha Luxmi,Aik-Howe Teo,Yang-Yang Qi,Li Yuan Lee,Rong-Juan Pei,Wei Deng,Zhong-Hui Xu,Jia-Ming Yang,Yan Zhang,Wuxiang Guan,Xiong Yu
DOI: https://doi.org/10.2139/ssrn.4066508
2022-01-01
SSRN Electronic Journal
Abstract:Background: Waning of neutralizing titers and decline of protection shorter after the second dose of COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a heterologous boosting using one dose recombinant SARS-CoV-2 fusion protein vaccine (V-01) in inactivated vaccine-primed population was studied, aimed to restore the immunity.Methods: A randomized, double-blind and placebo-controlled phase Ⅲ trial was conducted in healthy people aged 18 years or older in Pakistan and Malaysia. Each eligible participant received one dose of V-01 vaccine developed by Livzon Mabpharm Inc . or placebo 3-6 months after the 2-dose primary regimen, and was monitored for safety and efficacy. The primary endpoint was protection against confirmed symptomatic SARS-CoV-2 infection.Results: A total of 10,218 participants were randomly assigned to receive vaccine or placebo. Virus-neutralizing antibodies were assessed in 419 participants. A dramatical increase (11.3-fold; 128.3 to 1452.8) of neutralizing titers was measured in V-01 group at 14 days after the booster. Over the two months surveillance, vaccine efficacy was 47.8% (95%CI: 22.6 to 64.7) according to the intention-to-treat principle. The most common adverse events were transient, mild-to-moderate pain at the injection site, fever, headache, and fatigue. Serious adverse events occurred almost equally in V-01 (0.12%) and placebo (0.16%) groups. Conclusion: The heterologous boosting with V-01 vaccine was safe, efficacious, and could elicit robust humoral immunity under the epidemic of the Omicron variant.Trial Registration Details: The study was registered with ClinicalTrials.gov (number: NCT05096832).Funding Information: Funded by Livzon Mabpharm Inc. Declaration of Interests: FJ, WD, and XY are employees of the Joincare Pharmaceutical Group Industry Co., Ltd.; ZHX, JMY, and YZ are employees of the Livzon Mabpharm Inc., Joincare holds Livzon. All other authors declare no competing interests.Ethics Approval Statement: The protocol was approved by the ethics review committees of each study sites, and written informed consent was obtained from each participant before enrollment.